Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2023-09-01 DOI:10.1158/2643-3230.BCD-23-0044

Bruno Paiva, Irene Manrique, Julie Rytlewski, Timothy Campbell, Christian C Kazanecki, Nathan Martin, Larry D Anderson, Jesús G Berdeja, Sagar Lonial, Noopur S Raje, Yi Lin, Philippe Moreau, Jesús F San-Miguel, Nikhil C Munshi, Shari M Kaiser

{"title":"Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.","authors":"Bruno Paiva, Irene Manrique, Julie Rytlewski, Timothy Campbell, Christian C Kazanecki, Nathan Martin, Larry D Anderson, Jesús G Berdeja, Sagar Lonial, Noopur S Raje, Yi Lin, Philippe Moreau, Jesús F San-Miguel, Nikhil C Munshi, Shari M Kaiser","doi":"10.1158/2643-3230.BCD-23-0044","DOIUrl":null,"url":null,"abstract":"The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10-6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.Significance: This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion. See related commentary by Landgren and Kazandjian, p. 346 . This article is featured in Selected Articles from This Issue, p. 337.","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":null,"pages":null},"PeriodicalIF":11.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472177/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2643-3230.BCD-23-0044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus

Significance: This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion. See related commentary by Landgren and Kazandjian, p. 346 . This article is featured in Selected Articles from This Issue, p. 337.

查看原文本刊更多论文

Idecbtagene Vicleucel后血清学和可测量残留疾病评估的时间依赖性预后价值。

可测量残留疾病（MRD）在用嵌合抗原受体（CAR）T细胞治疗的多发性骨髓瘤患者中的作用尚不确定。我们分析了125名KarMMa中复发/难治性多发性骨髓瘤患者输注依卡他定-维勒（ide-cel）后第一年的MRD动力学。在ide cel后第1个月，不完全缓解（CR）患者与CR患者的无进展生存期（PFS）没有差异；只有MRD状态可以预测这一里程碑显著不同的PFS。在3个月及以上MRD检测不到的患者中，与显著性相比，CR患者的PFS更长：这是评估CAR T治疗复发/难治性多发性骨髓瘤后CR和MRD动力学影响的首批研究之一。这些数据有助于解释CAR T细胞输注后早期和晚期血清学和MRD反应的预后意义。见Landgren和Kazandjian的相关评论，第346页。这篇文章刊登在本期精选文章中，第337页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.